| Recruiting | Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective NCT07302607 | University Hospital, Strasbourg, France | — |
| Withdrawn | Sargramostim (GM-CSF) + PD-1 NCT04703426 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting NCT05079113 | Case Comprehensive Cancer Center | — |
| Active Not Recruiting | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Thera NCT03719131 | Emory University | Phase 2 |
| Unknown | Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhi NCT03385486 | Taiga Biotechnologies, Inc. | Phase 1 |
| Completed | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma NCT04059224 | Universitair Ziekenhuis Brussel | Phase 2 |
| Completed | Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma NCT03200847 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Completed | Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melano NCT02676869 | Immutep Australia Pty. Ltd. | Phase 1 |
| Completed | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma NCT02306850 | St. Louis University | Phase 2 |
| Terminated | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma NCT01875653 | Lisata Therapeutics, Inc. | Phase 3 |
| Completed | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma NCT02073123 | NewLink Genetics Corporation | Phase 1 / Phase 2 |
| Completed | Interferon Toxicities in Melanoma Treatment NCT02794636 | Bristol-Myers Squibb | — |
| Completed | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in NCT01726738 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma NCT01376713 | Medical University of Vienna | Phase 2 |
| Terminated | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Mel NCT01026051 | Mannkind Corporation | Phase 2 |
| Completed | Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanom NCT01107665 | University of California, Irvine | Phase 2 |
| Unknown | Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. NCT01168050 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-I NCT00945269 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00450255 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT01851408 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma NCT00349206 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Sta NCT00217542 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00119249 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tanespimycin in Treating Patients With Stage III-IV Melanoma NCT00087386 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma NCT00082875 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers NCT00074308 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Decitabine in Treating Patients With Advanced Solid Tumors NCT00030615 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm NCT00003789 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003646 | Vical | Phase 2 |
| Completed | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma NCT00003647 | Vical | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma NCT00019890 | National Cancer Institute (NCI) | Phase 2 |